Clinical trials of EZH2 inhibitors in malignant rhabdoid tumours, small cell carcinoma of hypercalcaemic type, SMARCA4 deficient thoracic sarcoma, and epithelioid sarcoma are ongoing [139,140]. Here, EZH2 is linked to rhabdoid tumor.